Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and neurodegenerative disorders. Numerous studies suggest that targeting BDNF and its TrkB receptor could be a promising therapeutic strategy for the treatment of brain disorders. However, the development of potent small ligands for the TrkB receptor has proven to be difficult. By using a peptidomimetic approach, we developed a highly potent and selective TrkB inhibitor, cyclotraxin-B, capable of altering TrkB-dependent molecular and physiological processes such as synaptic plasticity, neuronal differentiation and BDNF-induced neurotoxicity. Cyclotraxin-B allosterically alters the conformation of TrkB, which leads to the inhibition of both BDNF-dependent and -independent (basal) activities. Finally, systemic administration of cyclotraxin-B to mice results in TrkB inhibition in the brain with specific anxiolytic-like behavioral effects and no antidepressant-like activity. This study demonstrates that cyclotraxin-B might not only be a powerful tool to investigate the role of BDNF and TrkB in physiology and pathology, but also represents a lead compound for the development of new therapeutic strategies to treat brain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Cyclotraxin-B inhibits normal and deleterious cellular signaling events associated with TrkB but not TrkA nor TrkC. (A-D) Cyclotraxin-B inhibits TrkB- but not TrkA- nor TrkC-dependent neurite outgrowth. (A) Representative photomicrographs of nnr5 PC12-TrkB cells treated for 48 h with cyclotraxin-B and/or BDNF. 20× magnification. (B) Quantitative analysis of BDNF-induced neurite outgrowth in presence of increasing concentrations of cyclotraxin-B. Data are mean ± s.e.m. (sixplicates; n = 5). (C) Quantitative analysis and representative western blot of total and phospho-MAPK in nnr5 PC12-TrkB cells treated as indicated. Data are mean ± s.e.m. (n = 4) and are expressed in percentage of basal condition; *** P<0.001 compared to control; §§§ P<0.001, compared to BDNF. (D) nnr5 PC12-TrkA and -TrkC cells were incubated with cyclotraxin-B (1 µM) in presence or not of NGF or NT-3, respectively. (E) Cyclotraxin-B prevents BDNF-induced neurons death. Cortical neurons were treated with cyclotraxin-B or BDNF, as described in methods. Data are mean ± s.e.m. (sixplicates, n = 5) expressed in percentage of control. *** P<0.001 compared to control; §§§ P<0.001, compared to BDNF. (F) Cyclotraxin-B inhibits cap-dependent protein translation in cortical neurons. [35S]-methionine incorporation into proteins (white bars) was measured in cortical neurons exposed to cyclotraxin-B, K252a and BDNF, as indicated. Phosphorylation of eIF4E was quantified by immunoblots (black bars). Data are mean ± s.e.m. (triplicates, n = 5) and are expressed in percentage of basal condition; * P<0.05, ** P<0.01, *** P<0.001, compared to respective basal condition; § P<0.05, §§ P<0.01, compared to respective BDNF condition. Inset shows correlations between TrkB-dependent protein synthesis and eIF4E phosphorylation. (1) K252a, (2) cyclotraxin-B, (3) basal, (4) BDNF + cyclotraxin-B, (5) BDNF.](https://figures.cochat.ai/paper-figures/3670adbaa54842babfec64f260d9d557/cyclotraxin-b-the-first-highly-potent-and-selective-trkb-inhibitor-has-figure-5.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While one study has observed anxiolytic properties, this molecule did not seem to display clear antidepressant effects (Cazorla et al. 2010)”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Cazorla et al. 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Behavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 3,320
Krishnan, V., Han, M.-H., Graham, D. L., Berton, O., Renthal, W., Russo, S. J., LaPlant, Q., Graham, A., Lutter, M., Lagace, D. C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.09.018 · Cited by 2,307 · cited 2×
“Our observations are in line with two recent studies demonstrating that mice susceptible to stress-related disorders after chronic social defeat have an overactivity of BDNF/TrkB signaling in their reward system [40,41].”
BackgroundResultEssential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129 · cited 2×
“Our observations are in line with two recent studies demonstrating that mice susceptible to stress-related disorders after chronic social defeat have an overactivity of BDNF/TrkB signaling in their reward system [40,41].”
BackgroundResultHippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor.
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., & Bonhoeffer, T. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8856 · Cited by 1,426 · cited 1×
“have reported a reduction within the same range, from about 190% to 135%, using BDNF knockout mice [51].”
MethodGenetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior
Chen, Z.-Y., Jing, D., Bath, K. G., Ieraci, A., Khan, T., Siao, C.-J., Herrera, D. G., Toth, M., Yang, C., McEwen, B. S., et al. (2006) · Science · doi:10.1126/science.1129663 · Cited by 1,340
New insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 4×
“There is an increasing literature that proposes TrkB receptor signaling as a promising target for the treatment of psychiatric disorders [13,14,15,16], but also epilepsy [9], neurodegenerative diseases [10,11,44], and even cancer [45].”
BackgroundInfluentialBDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis
Bramham, C. R., & Messaoudi, E. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.003 · Cited by 1,193 · cited 2×
“modulation of synaptic plasticity [8].”
Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958 · cited 1×
“Competition binding studies were done mainly as previously described [55].”
MethodMurer, M. G., Yan, Q., & Raisman-Vozari, R. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00014-9 · Cited by 874 · cited 1×
“There is an increasing literature that proposes TrkB receptor signaling as a promising target for the treatment of psychiatric disorders [13,14,15,16], but also epilepsy [9], neurodegenerative diseases [10,11,44], and even cancer [45].”
Backgroundp75 and Trk: A two-receptor system
Chao, M. V., & Hempstead, B. L. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93922-k · Cited by 857
Cited by
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
“Targeting the extracellular domains of the receptor TPKs and others by peptide-mimetics, ‘peptoids’ or antibodies is another special case of type-3 inhibitors (Fleishman et al., 2002; Udugamasooriya et al., 2008; Cazorla et al., 2010; Jura et al., 2011; Christopoulos et al., 2014).”
BackgroundOkamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L., & Kurzrock, R. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00183 · Cited by 328
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Metadata
- Authors
- Cazorla, M., Jouvenceau, A., Rose, C., Guilloux, J.-P., Pilon, C., Dranovsky, A., & Prémont, J.
- Affiliations
- Inserm (FR)
- New York State Psychiatric Institute (US)
- Corresponding author
- Cazorla, Maxime
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-03-19
- Volume
- 5
- Issue
- 3
- Pages
- e9777
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2841647
- OpenAlex
- W1977999433
- Cited by
- 99
- References
- 62
- Citations by year
- 2026: 7 · 2025: 1 · 2024: 4 · 2023: 4 · 2022: 9 · 2021: 7 · 2020: 5 · 2019: 1 · 2018: 10 · 2017: 5 · 2016: 7 · 2015: 5 · 2014: 8 · 2013: 7 · 2012: 8
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- National Institute of Mental Health (R01MH091844, K08MH079088)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- TrkB receptor, brain-derived neurotrophic factor, anxiolytic effects, peptidomimetic inhibitors, allosteric inhibition, synaptic plasticity, neuronal differentiation, antidepressant-like effects, brain disorders, lead compounds
- MeSH terms
- Animals, Antidepressive Agents, Brain, Brain Diseases, Electrophysiology, Enzyme-Linked Immunosorbent Assay, Male, Neurons, Peptides, Cyclic, Phosphorylation, Anti-Anxiety Agents, PC12 Cells, Rats, Sprague-Dawley, Long-Term Potentiation, Brain-Derived Neurotrophic Factor, Receptor, trkB, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0009777
- The paper
- Cazorla, M., Jouvenceau, A., Rose, C., Guilloux, J.-P., Pilon, C., Dranovsky, A., & Prémont, J. (2010). Cyclotraxin-B, the First Highly Potent and Selective TrkB Inhibitor, Has Anxiolytic Properties in Mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0009777
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.